What is CVE-2021-38371?

CVE-2021-38371 is a high-severity vulnerability in Exim, classified under Improper Neutralization of Special Elements in Output Used by a Downstream Component (Injection). CVSS score: 7.5/10. Published 2021-08-10.

How severe is CVE-2021-38371?

High severity. CVSS v3 base score is 7.5 out of 10.

Is CVE-2021-38371 known to be exploited?

5 public proof-of-concept repositories are indexed. Not currently listed in the CISA KEV catalog.

Vulnerability in Exim

CVE-2021-38371

The STARTTLS feature in Exim through 4.94.2 allows response injection (buffering) during MTA SMTP sending.

EPSS: 0.020 (78.6th percentile) — read the EPSS interpretation.

CVSS v3 metric

CVSS v3 base score 7.5 (High). Vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:N.

Affected products

Exim
N/a — versions n/a

Weakness classification (CWE)

CWE-74 — Improper Neutralization of Special Elements in Output Used by a Downstream Component (Injection)

Public proof-of-concept exploits

References

cve@mitre.org (x_refsource_MISC, Tool Signature)
cve@mitre.org (Product, x_refsource_MISC)
cve@mitre.org (x_refsource_MISC, Broken Link, Vendor Advisory)
af854a3a-2127-422b-91ae-364da2661108

Frequently asked questions

What is CVE-2021-38371?: CVE-2021-38371 is a high-severity vulnerability in Exim, classified under Improper Neutralization of Special Elements in Output Used by a Downstream Component (Injection). CVSS score: 7.5/10. Published 2021-08-10.
How severe is CVE-2021-38371?: High severity. CVSS v3 base score is 7.5 out of 10.
Is CVE-2021-38371 known to be exploited?: 5 public proof-of-concept repositories are indexed. Not currently listed in the CISA KEV catalog.